-
My Account
My Account
66.45 (1.44%) 73.4 (1.59%) 
1.10 pm | 28 Dec 2006
Ambareesh Baliga of Karvy Stock Broking is of the view that Dr Reddy's Laboratories can touch Rs 840-880....
12.53 pm | 28 Dec 2006
Technical Analyst, Ashwani Gujral is of the view that above Rs 820, Dr Reddy's Laboratories has target of Rs 910....
11.36 am | 28 Dec 2006
Broking house, Karvy Stock Broking is bullish on Dr Reddy’s Laboratories and believes that it would be a market performer with a target price of Rs 84...
11.16 am | 28 Dec 2006
Broking house, Angel Broking has maintained hold rating on the Dr Reddys Laboratories with a target price of Rs 900....
8.28 am | 28 Dec 2006
Dr Reddy's Laboratories Ltd today got the final approval for Ondansetron Hydrochloride, the generic equivalent of the blockbuster drug `Zofran', from ...
6.53 pm | 27 Dec 2006
Rajen Shah of Angel Broking is of the view that Dr Reddy's reasonably priced at current levels so investors should hold on to it....
5.48 pm | 27 Dec 2006
Technical Analyst, Sudarshan Sukhani not very upbeat in the short-term in Dr Reddys Laboratories....
3.10 pm | 27 Dec 2006
VC & CEO of Dr Reddy's Laboratories, GV Prasad comments on getting the exclusivity for Ondansetron soon after the rights for Simvastatin and Proscar g...
1.25 pm | 27 Dec 2006
Dr Reddy’s announces final approval of Ondansetron tablets with 180-days of marketing exclusivity...
6.13 pm | 26 Dec 2006
Perlecan Pharma moves Dr Reddy’s novel anti-diabetic drug candidate to Phase I clinical trial...
5.02 pm | 13 Dec 2006
Technical Analyst, Prakash Gaba is of the view that Associated Cement Companies, ACC, Grasim Industries looks good in cement pack....
6.18 pm | 12 Dec 2006
Dr Reddy has crossed a billion dollars in revenues, and that makes it the second Indian company after Ranbaxy to scale the magic figure, reports CNBC-...
3.45 pm | 12 Dec 2006
Shishir Kedia of Anand Rathi Securities is of the view that Ranbaxy can touch Rs 350 levels....
3.46 pm | 11 Dec 2006
Broking house, DSP Merrill Lynch is bullish on Dr Reddy's Laboratories and has maintained buy rating on the stock....
10.54 am | 08 Dec 2006
Dr Reddy's is looking at acquisition in European markets. CEO Satish Reddy added the company is also gearing up for the launch of their new poly pill,...
8.15 am | 08 Dec 2006
Researchers at the University of Auckland have teamed up with Dr Reddy's Laboratories, Hyderabad to undertake trials of a new Polypill that could prov...
12.13 pm | 06 Dec 2006
Ambareesh Baliga of Karvy Stock Broking feels that Cipla can add another Rs 80-85 in 12-15 month time frame....
8.10 pm | 04 Dec 2006
In Europe they are called biosimilars and the us FDA calls them follow on protein products but copies of biotech drugs could be the next big opportuni...
2.57 pm | 01 Dec 2006
Broking house, Motilal Oswal has recommended buy rating Dr Reddy's Laboratories with a target of Rs 800....
